| 1 |
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis [J]. Am J Med, 1993, 94(6): 646-650.
|
| 2 |
Burge R, Dawson-Hughes B, Solomon D H, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 [J]. J Bone Miner Res, 2007, 22(3): 465-475.
|
| 3 |
Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline [J]. J Clin Endocrinol Metab, 2019, 104(5): 1595-1622.
|
| 4 |
Chew CK, Clarke BL. Abaloparatide: recombinant human PTHrP (1-34) anabolic therapy for osteoporosis [J]. Maturitas, 2017, 97: 53-60
|
| 5 |
Michael RM, MD, Nicholas CH, et al. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis[J]. Menopause, 2018, 25(7): 767-771.
|
| 6 |
Lorentzon M. Treating osteoporosis to prevent fractures: current concepts and future developments [J]. J Intern Med, 2019, 285(4): 381-394.
|
| 7 |
Eastell R, Rosen CJ. Response to letter to the editor: "pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline" [J]. J Clin Endocrinol Metab, 2019, 104(8): 3537-3538.
|
| 8 |
Anagnostis P, Paschou S, Mintziori G, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement [J]. Maturitas, 2017, 101: 23-30.
|
| 9 |
Silverman S, Langdahl BL, Fujiwara S, et al. Reduction of hip and other fractures in patients receiving teriparatide in Real-World clinical practice: integrated analysis of four prospective observational studies [J]. Calcif Tissue Int, 2019, 104(2): 193-200.
|
| 10 |
Sahbani K, Cardozo CP, Bauman WA, et al. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide [J]. Physiol Rep, 2019, 7(19): e14225.
|
| 11 |
Anagnostis P, Gkekas NK, Potoupnis M, et al. New therapeutic targets for osteoporosis [J]. Maturitas, 2019, 120: 1-6.
|
| 12 |
Beall DP, Feldman RG, Gordon ML, et al. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study [J]. Osteoporos Int, 2016, 27(3): 1191-1198.
|
| 13 |
Cheloha RW, Gellman SH, Vilardaga J. PTH receptor-1 signalling-mechanistic insights and therapeutic prospects [J]. Nat Rev Endocrinol, 2015, 11(12): 712-724.
|
| 14 |
Fischer J, Aulmann A, Dexheimer V, et al. Intermittent PTHrP(1-34) exposure augments chondrogenesis and reduces hypertrophy of mesenchymal stromal cells [J]. Stem Cells Dev, 2014, 23(20): 2513-2523.
|
| 15 |
Kanis JA, Odén A, Mccloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide [J]. Osteoporos Int, 2012, 23(9): 2239-2256.
|
| 16 |
Panula J, Pihlajamäki H, Mattila VM, et al. Mortality and cause of death in hip fracture patients aged 65 or older - a population-based study [J]. BMC Musculoskelet Disord, 2011, 12(1): 105.
|
| 17 |
Osteoporosis Foundation Facts Statistics. International Osteoporosis Foundation website.
URL
|
| 18 |
Leslie WD, Metge CJ, Azimaee M, et al. Direct costs of fractures in Canada and trends 1996-2006: a population-based cost-of-illness analysis [J]. J Bone Miner Res, 2011, 26(10): 2419-2429.
|
| 19 |
Ensrud K, Crandall CJ. Osteoporosis [J]. Ann Intern Med, 2017, 167(3): ITC17-ITC32.
|
| 20 |
Saag KG, Williams SA, Wang Y, et al. Effect of abaloparatide on bone mineral density and fracture incidence in a subset of younger postmenopausal women with osteoporosis at high risk for fracture [J]. Clin Ther, 2020, 42(6): 1099-1107.e1.
|
| 21 |
Mccauley LK, Martin TJ. Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine [J]. J Bone Miner Res, 2012, 27(6): 1231-1239.
|
| 22 |
Revollo L, Kading J, Jeong SY, et al. N-cadherin restrains PTH activation of Lrp6/β-catenin signaling and osteoanabolic action [J]. J Bone Miner Res, 2015, 30(2): 274-285.
|
| 23 |
Silva BC, Bilezikian JP. Parathyroid hormone: anabolic and catabolic actions on the skeleton [J]. Curr Opin Pharmacol, 2015, 22(10): 41-50.
|
| 24 |
de Castro L F, Lozano D, Portal-Nunez S, et al. Comparison of the skeletal effects induced by daily administration of PTHrP (1-36) and PTHrP (107-139) to ovariectomized mice[J]. J Cell Physiol,2012,227(4):1752-1760.
|
| 25 |
Minisola S, Cipriani C, Occhiuto M, et al. New anabolic therapies for osteoporosis[J]. Intern Emerg Med,2017,12(7):915-921.
|
| 26 |
Shirley M. Abaloparatide: first global approval [J]. Drugs, 2017, 77(12): 1363-1368.
|
| 27 |
Hattersley G, Dean T, Corbin BA, et al. Binding selectivity of abaloparatide for PTH-Type-1-Receptor conformations and effects on downstream signaling [J]. Endocrinology, 2016, 157(1): 141-149.
|
| 28 |
Xu J, Rong H, Ji H, et al. Effects of different dosages of parathyroid hormone-related protein 1-34 on the bone metabolism of the ovariectomized rat model of osteoporosis [J]. Calcif Tissue Int, 2013, 93(3): 276-287.
|
| 29 |
Varela A, Chouinard L, Lesage E, et al. One year of abaloparatide*, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption [J]. J Bone Miner Res, 2017, 32(1): 24-33.
|
| 30 |
Doyle N, Varela A, Haile S, et al. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption [J]. Osteoporos Int, 2018, 29(3): 685-697.
|
| 31 |
Gonnelli S, Caffarelli C. Abaloparatide [J]. Clin Cases Miner Bone Metab, 2016, 13(2): 106-109.
|
| 32 |
Yusuf A, Cummings SR, Watts NB, et al. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women [J]. Arch Osteoporos, 2018, 13(1): 33.
|
| 33 |
Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical trial [J]. JAMA, 2016, 316(7): 722-733.
|
| 34 |
Mccloskey EV, Johansson H, Oden A, et al. The effect of Abaloparatide-SC on fracture risk is Independent of baseline FRAX fracture probability: a post Hoc analysis of the ACTIVE study [J]. J Bone Miner Res, 2017, 32(8): 1625-1631.
|
| 35 |
Sleeman A, Clements JN. Abaloparatide: a new pharmacological option for osteoporosis [J]. Am J Health Syst Pharm, 2019, 76(3): 130-135.
|
| 36 |
Leder B Z, Mitlak B, Hu M Y, et al. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis[J]. J Clin Endocrinol Metab,2020,105(3).
|
| 37 |
Bilezikian JP, Hattersley G, Mitlak BH, et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial [J]. Curr Med Res Opin, 2019, 35(12): 2097-2102.
|
| 38 |
Watts NB, Hattersley G, Fitzpatrick LA, et al. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis [J]. Osteoporos Int, 2019, 30(6): 1187-1194.
|
| 39 |
Cosman F. The evolving role of anabolic therapy in the treatment of osteoporosis [J]. Curr Opin Rheumatol, 2019, 31(4): 376-380.
|
| 40 |
Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis [J]. Curr Opin Rheumatol, 2002, 14(4): 433-440.
|
| 41 |
Ma YL, Marin F, Stepan J, et al. Comparative effects of teriparatide and Strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis [J]. Bone, 2011, 48(5): 972-978.
|
| 42 |
Miller PD, Hattersley G, Lau E, et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial [J]. Bone, 2019, 120: 137-140.
|
| 43 |
Esbrit P, Alcaraz M J. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies [J]. Biochem Pharmacol, 2013, 85(10): 1417-1423.
|
| 44 |
Leder BZ. Parathyroid hormone and parathyroid Hormone-Related protein analogs in osteoporosis therapy [J]. Curr Osteoporos Rep,2017, 15(2): 110-119.
|
| 45 |
US FDA. TymlosTM (abaloparatide) injection, for subcutaneous use: US prescribing information. 2017. Accessed 30 May 2017.
URL
|
| 46 |
Jolette J, Attalla B, Varela A, et al. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34) [J]. Regul Toxicol Pharmacol, 2017, 86: 356-365.
|
| 47 |
Maycas M, Mcandrews KA, Sato AY, et al. PTHrP-Derived peptides restore bone mass and strength in diabetic mice: additive effect of mechanical loading [J]. J Bone Miner Res, 2017, 32(3): 486-497.
|
| 48 |
Chow S K, Leung K S, Qin J, et al. Mechanical stimulation enhanced estrogen receptor expression and callus formation in diaphyseal long bone fracture healing in ovariectomy-induced osteoporotic rats[J]. Osteoporos Int,2016,27(10):2989-3000.
|
| 49 |
Bortoluzzi A, Furini F, Scirè CA. Osteoarthritis and its management-Epidemiology, nutritional aspects and environmental factors [J]. Autoimmun Rev, 2018, 17(11): 1097-1104.
|
| 50 |
Sampson E R, Hilton M J, Tian Y, et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis[J]. Sci Transl Med,2011,3(101):101r-193r.
|
| 51 |
Cao X, Duan Z, Yan Z, et al. miR-195 contributes to human osteoarthritis via targeting PTHrP [J]. J Bone Miner Metab, 2019, 37(4): 711-721.
|